This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.
Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses / M. Rovaris, M. Codella, L. Moiola, A. Ghezzi, M. Zaffaroni, G. Mancardi, E. Capello, F. Sardanelli, G. Comi, M. Filippi. - In: NEUROLOGY. - ISSN 0028-3878. - 59:9(2002 Nov 12), pp. 1429-32-1432.
Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses
F. Sardanelli;
2002
Abstract
This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.